Core Viewpoint - The company has announced a delay in the "Malic Acid Co-production Tryptophan Project," extending the expected operational date from 2025 to October 2026 due to project implementation and investment progress considerations [5][6][7]. Fundraising and Investment Project Overview - The company raised approximately RMB 699.99 million through a private placement of 21,122,510 shares at RMB 33.14 per share, with net proceeds after expenses amounting to RMB 683.81 million [1][2]. - The total planned investment for the projects was adjusted from RMB 700 million to RMB 683.81 million, with specific allocations for projects detailed in a table [2][3]. Fund Usage and Project Status - As of June 30, 2025, the company has fully utilized the raised funds for the "Succinic Acid Co-production Valine/Inositol Project" and the "Malic Acid Co-production Tryptophan Project," with investment ratios exceeding 100% for both projects [4]. - The company has established a special account for the management of the raised funds, ensuring compliance with regulatory requirements [2][3]. Delay Reasons and Impact - The delay in the "Malic Acid Co-production Tryptophan Project" is based on the need for technical upgrades to production equipment and alignment with market demand [5][6]. - The company asserts that the delay will not affect the project's investment direction, implementation entity, or method, and it does not pose any risk to shareholder interests [6][7]. Approval and Compliance - The board of directors and the supervisory board have approved the delay, and the decision complies with relevant regulations and internal governance [7][8].

Core Points - The candidate, Chen Jizhong, has been nominated as an independent director for Anhui Huaheng Biotechnology Co., Ltd. and confirms his qualifications and independence [1][4] - The candidate has over 5 years of relevant work experience in law, economics, accounting, finance, or management, and commits to attending the necessary training for independent directors [1][4] - The candidate declares that he meets the legal and regulatory requirements for independent directors as outlined by various Chinese laws and regulations [2][3][4] Summary by Sections - **Qualifications and Experience** - The candidate possesses basic knowledge of listed company operations and relevant laws and regulations, with over 5 years of experience in necessary fields [1][4] - The candidate has not yet obtained the required training certification but commits to completing the training [1][4] - **Independence Criteria** - The candidate confirms independence by stating he does not fall under any disqualifying conditions, such as holding significant shares or having close relationships with major stakeholders [2][3] - The candidate has no adverse records in the last 36 months, including no administrative or criminal penalties from regulatory bodies [3][4] - **Commitment to Responsibilities** - The candidate acknowledges the responsibilities of an independent director and guarantees the truthfulness and completeness of his statements [5][6] - The candidate commits to complying with all relevant laws and regulations during his tenure and will resign if he no longer meets the independence criteria [6]

Group 1 - The company held its 23rd meeting of the fourth board of directors, where it approved the election of a new independent director and adjustments to the specialized committees and their members [1][2] - Independent director Zhang Qifeng will step down after serving for six years, and the company will continue to fulfill his duties until a new independent director is elected at the shareholders' meeting [1][2] - Chen Jizhong has been nominated as the independent director candidate, pending approval from the Shanghai Stock Exchange and the shareholders' meeting [2][5] Group 2 - The company has restructured its specialized committees, changing the original nomination, remuneration, and assessment committee into separate nomination and remuneration committees [2][3] - The new composition of the specialized committees includes the Strategy and ESG Committee, Audit Committee, Nomination Committee, and Remuneration and Assessment Committee, each consisting of three members [3] - Chen Jizhong will serve as the convener of the Audit Committee upon his election as an independent director [3]

Core Viewpoint - The company has elected MAO JIANWEN as the employee representative director for its fourth board of directors, ensuring compliance with relevant laws and regulations [1][2][3]. Group 1: Election Details - The election took place during the first employee representative meeting on September 4, 2025, where MAO JIANWEN was approved as the employee representative director [1]. - MAO JIANWEN previously served as a director on the fourth board and will now hold the position of employee representative director, with no changes to the overall composition of the board [1]. Group 2: Compliance and Qualifications - The board's composition, including directors who are also senior management and employee representatives, does not exceed half of the total number of directors [1]. - MAO JIANWEN holds a bachelor's degree in applied chemistry and a PhD from the University of Strathclyde, with extensive experience in leadership roles at Ciba and BASF [4]. - He currently holds 210,250 shares in the company, representing 0.08% of the total share capital, and has no conflicts of interest with major stakeholders [4].

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange, necessitating revisions and formulations of internal governance systems to comply with relevant regulations [1][2]. Group 1: Governance System Revisions - The company held its 23rd meeting of the 4th Board of Directors on September 4, 2025, where it approved the proposal to revise and formulate internal governance systems applicable after the issuance of H-shares [1]. - The governance systems to be revised or formulated include a total of 18 items, with the first 6 requiring approval from the shareholders' meeting and the remaining 12 approved by the Board of Directors [2]. - The revised governance system drafts were disclosed on the Shanghai Stock Exchange website on the same day as the board meeting [2]. Group 2: Implementation and Authorization - The revised governance systems will take effect from the date of the company's H-share listing, while the existing governance systems will remain in effect until further revisions are made [2]. - The shareholders' meeting is requested to authorize the Board of Directors and/or its authorized personnel to make adjustments and modifications to the approved documents as necessary, based on domestic and foreign laws and regulations [2].

Core Points - The article outlines the share repurchase management system of Anhui Huaheng Biotechnology Co., Ltd, aiming to regulate share buybacks and protect investors' rights [2][3][4] Group 1: General Principles - The company establishes this system based on various laws and regulations, including the Company Law and Securities Law, to standardize share repurchase behavior [2] - The company may repurchase shares under specific circumstances, such as reducing registered capital, employee stock ownership plans, or maintaining company value and shareholder rights [2][3] - The board of directors must consider the company's financial status and ensure that repurchase plans align with actual financial conditions [3][4] Group 2: Implementation Regulations - The company must ensure that share repurchases comply with legal requirements and do not harm the rights of shareholders and creditors [3][4] - The repurchase can be conducted through methods such as centralized bidding or tender offers, and the company must disclose the repurchase plan and its purpose [5][10] - The repurchase period is limited to a maximum of twelve months for certain conditions and three months for others [6][12] Group 3: Funding and Pricing - The funds for repurchase must be legally sourced, including self-owned funds, funds raised from issuing preferred shares or bonds, and other legitimate sources [14][15] - The company must set a reasonable price range for the repurchase, ensuring that the upper limit does not exceed 150% of the average trading price over the previous 30 trading days [16][17] Group 4: Disclosure and Reporting - The company is required to disclose the progress of share repurchases regularly, including the number of shares repurchased and the total amount spent [35][36] - Any changes to the repurchase plan must be disclosed promptly, along with the reasons for such changes [36][37] Group 5: Handling of Repurchased Shares - Repurchased shares must be handled according to the disclosed purposes, and if not transferred as planned, they must be canceled after a three-year holding period [46][47] - The company must report the results of the repurchase and any changes in shareholding structure after the completion of the repurchase [48][49]

Core Viewpoint - The document outlines the information disclosure management system of Anhui Huaheng Biotechnology Co., Ltd, emphasizing the importance of accurate, timely, and fair information disclosure to protect the rights of the company and its investors [1][2]. Group 1: General Principles - The information disclosure management system is established to ensure the company's operations are standardized and to manage information disclosure affairs effectively [1]. - The system applies to various personnel and institutions within the company, including the board of directors, senior management, and other relevant parties [1][2]. Group 2: Basic Principles of Information Disclosure - The company must adhere to the principle of fair information disclosure, ensuring all investors receive the same information simultaneously [4][5]. - Information must be disclosed in a timely manner, defined as within two trading days from the triggering event [6]. - Disclosures should be based on objective facts and should not contain misleading statements or exaggerations [7][8]. Group 3: Content of Information Disclosure - Regular reports include annual, semi-annual, and quarterly reports, which must disclose any information that significantly impacts investor decision-making [22][23]. - The annual report must be audited by a qualified accounting firm, while the semi-annual report may not require an audit unless specific conditions are met [22][23]. Group 4: Procedures for Information Disclosure - The process for disclosing information involves several steps, including application, review, and publication, with the board secretary playing a crucial role [35][36]. - Major events must be reported immediately, detailing the cause, current status, and potential impact [29][30]. Group 5: Responsibilities and Management - The chairman of the board is the primary responsible person for information disclosure, while the board secretary manages the day-to-day affairs [42][43]. - The securities investment department is responsible for drafting and managing the disclosure of regular and temporary reports [43][44]. Group 6: Confidentiality Measures - Individuals with insider information are required to maintain confidentiality and are prohibited from disclosing such information before it is officially released [52][53]. - The company may establish internal confidentiality protocols to manage the flow of sensitive information [53][54].

Core Points - The article outlines the external investment management system of Anhui Huaheng Biotechnology Co., Ltd, aiming to strengthen internal control and management of external investments, prevent errors, fraud, and risks, and enhance investment efficiency [2][3]. Group 1: External Investment Definition and Principles - External investment refers to the company's investment activities, including risk investments such as securities and derivatives, and long-term equity investments that are not intended for immediate liquidation [2]. - The principles of external investment include compliance with national laws and regulations and alignment with national industrial policies [3]. Group 2: Decision-Making and Approval Process - The decision-making bodies for external investments include the shareholders' meeting, board of directors, and chairman, each with specific authority [4]. - Investments meeting certain thresholds must be submitted for board review, including transactions where total asset value exceeds 10% of the latest audited total assets or where transaction amounts exceed 10% of the company's market value [4][5]. - For significant investments, board approval is required before submission to the shareholders' meeting [5]. Group 3: Management and Oversight - The investment business department is responsible for collecting information, evaluating projects, and monitoring the implementation of annual investment plans [11]. - The board's audit committee conducts regular audits of external investments, ensuring that projects meet expected benefits and reporting any underperforming projects [8]. Group 4: Financial Management and Auditing - The finance department maintains comprehensive financial records for external investment projects, ensuring compliance with accounting standards [23]. - Regular audits of controlling subsidiaries are conducted to analyze financial conditions and protect the company's interests [25][26]. Group 5: Personnel Management - The company appoints or recommends directors and senior management for invested companies, ensuring they fulfill their responsibilities and report on investment conditions [20][21].

Core Viewpoint - The document outlines the fundraising management system of Anhui Huaheng Biotechnology Co., Ltd., emphasizing the importance of proper management, usage, and supervision of raised funds to enhance efficiency and effectiveness in line with national policies and regulations [2][3]. Fundraising Management - The company must ensure that raised funds are used exclusively for designated purposes, primarily in main business areas that enhance competitiveness and innovation [2][3]. - The board of directors is responsible for monitoring the management and usage of raised funds to prevent investment risks and ensure safety [3][4]. - Related parties, including major shareholders and actual controllers, are prohibited from misusing the raised funds for personal gain [3][4]. Fund Storage and Usage - Raised funds must be stored in a dedicated account approved by the board of directors, and a tripartite supervision agreement must be signed with the financial advisor and the bank within one month of fund receipt [4][5]. - The company is required to use the raised funds according to the investment plan outlined in the issuance application documents, and any significant deviations must be promptly disclosed [5][6]. Project Management - The company must establish project management systems to monitor the application of funds, project progress, and quality [6][7]. - If a project faces significant changes in market conditions or delays, the company must reassess its feasibility and disclose the findings [6][7]. Cash Management - Temporarily idle raised funds can be managed through cash management products, which must be safe and liquid, with specific conditions outlined [8][9]. - Any temporary use of raised funds for working capital must be approved by the board and disclosed [9][10]. Use of Excess Funds - Excess funds must be allocated to ongoing or new projects, or for share repurchases, with a clear plan disclosed to shareholders [10][11]. - Any changes in the use of raised funds must be approved by the board and disclosed, ensuring that new projects align with the company's main business [12][13]. Reporting and Supervision - The company must provide accurate and complete disclosures regarding the actual use of raised funds, including any significant impacts on investment plans [26][27]. - An annual report must include verification from accounting firms regarding the management and usage of raised funds [14][15].

Core Points - The document outlines the management system for related party transactions of Anhui Huaheng Biotechnology Co., Ltd, aiming to standardize transactions and protect the interests of the company and its shareholders [1][2][3] Group 1: General Principles - Related party transactions must adhere to principles of honesty, equality, voluntariness, fairness, openness, and impartiality [1] - The company should take measures to regulate related party transactions to minimize and avoid them [1] Group 2: Definition of Related Parties - Individuals or entities that control the company directly or indirectly, hold more than 5% of shares, or are company directors or senior management are considered related parties [2][3] - Related transactions include asset purchases or sales, external investments, project transfers, and other transactions that may lead to resource or obligation transfers [3][4] Group 3: Decision-Making Procedures - Related directors must abstain from voting on related party transactions, and decisions require a majority of non-related directors [4][5] - Related shareholders must also abstain from voting, and their shares will not count towards the total valid votes [5][6] Group 4: Approval and Disclosure Requirements - Transactions exceeding certain thresholds must be approved by independent directors and disclosed [6][7] - Transactions with related individuals over 300,000 yuan or with related entities exceeding 0.1% of total assets or 3 million yuan require board approval [6][7] Group 5: Financial Assistance and Guarantees - The company is prohibited from providing financial assistance to related parties, except under specific conditions [8][9] - Guarantees for related parties require approval from a majority of non-related directors and must be disclosed to shareholders [7][8] Group 6: Compliance and Accountability - The company must take protective measures against losses caused by related parties and hold responsible individuals accountable [11][12] - Financial management must adhere to strict regulations when dealing with related parties to prevent misuse of company resources [12][14] Group 7: Miscellaneous Provisions - The document specifies that the term "above" includes the stated number, while "below" and "exceed" do not [15] - The market value for related transaction disclosures is defined as the average closing market value over the 10 trading days prior to the disclosure [15]